Pioneering Targeted Delivery of Genetic Medicines
Code Bio is developing a transformational, new class of precision genetic medicines to treat life-threatening diseases.
Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity.
The Company is advancing an internal pipeline focusing on a variety of diseases with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). Code Bio also has research programs underway based on targeting data focused in the lungs, pancreas, and liver.
Our 3DNA platform is engineered to overcome serious limitations of delivering genetic medicines by improving cell specific targeting and bioavailability, as well as offering modularity to deliver multiple modalities while minimizing off-target effects.
We are advancing an internal pipeline of genetic medicines to treat rare and prevalent diseases, with our most advanced research in Duchenne Muscular Dystrophy (DMD).
Partner with Us
We are actively engaged in establishing partnerships to take forward strategic programs that hold promise for genetic diseases.